克拉里斯罗米辛与安慰剂对心房的风险的影响
Gorm Boje Jensen1,2, Markus Harboe Olsen3,4, Magnus Thorsten Jensen4,5
1Copenhagen City Heart Study, Copenhagen University Hospital - Frederiksberg Hospital.
Danish medical journal
|March 3, 2026
概括
在患有稳定的心脏病的患者中,简短的克拉里思罗米辛疗程并没有增加新的心房动 (AF). 这一发现表明,在这个人群中,关于AF发病率的克拉里素是安全的.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 克拉里科尔试验表明,克拉里素可能会增加死亡率,可能是由于心律失常.
- 心房动 (AF) 是一种常见的心律失常症,也是显著的心血管风险因素.
研究的目的:
- 在患有稳定缺血性心脏病的患者中,对简短的克拉里素治疗方案后新发性心房动 (AF) 的发生率进行调查.
主要方法:
- 对CLARICOR试验的后期分析,涉及4372名患者,随机分配给克拉里胺或安慰剂.
- 使用国家登记册,AF发病率被追踪了十年.
- 考克斯的比例危险模型被用来评估克拉里素对AF发生的影响.
主要成果:
- 在十年的随访期间,13.5%的克拉里素组和13.3%的安慰剂组发展了AF.
- 考克斯分析显示,在克拉里思罗米辛和安慰剂组之间的AF发病率没有统计学上显著的差异 (HR = 1.09; 95% CI: 0.92-1.29; p = 0.32).
结论:
- 在慢性稳定性缺血性心脏病患者中,短时间的克拉里思罗米治疗并没有增加发展新的心房动的风险.
更多相关视频
相关概念视频
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...


